The Evarrest fibrin sealant patch from Ethicon is a flexible sealant patch designed for general hemostasis. It has a durable mechanical structure for integrated clot formation and has hemostatic efficacy upon first-use attempt, according to the company. It doesn’t require preparation, mixing or moistening – and is ready right out of the box. It has a shelf life of 30 months as well. Thousands of woven fibers and active human biologics work together to stop bleeding in tumor bed, liver resection and aortic reconstruction in 3 minutes. When applied, blood passes through the patch and clot formation begins at the bleeding surface and within the patch. The adhesives on the patch form a tight physical seal with tissue and the patch keeps its flexible barrier to bleeding. The patch is fully absorbed in eight weeks.
Thanks for pointing out. Our sister publication MassDevice actually reported in September that some researchers found an “unusually high” rate of early failure related to the Attune knee systems tibial components. http://www.massdevice.com/report-depuys-attune-knee-seeing-unusually-high-rate-early-failure/ I added a mention of the news to the slide about Attune. Perhaps the Prix Galien USA Committee was too soon to highlight Attune as innovative?
Balint Frankosays
I’d like to know how did you measure “innovative” properties of a medical device? What was the standard for measurement? Your list, looks very subjective and misleading.
Chris Newmarkersays
Thanks for the comment, Balint. The list includes the 11 medical technology nominees for the 11th Annual Prix Galien USA Award from the Galien Foundation. They said the nominees were chosen by a judging committee of “13 renowned leaders from the biomedical industry and academia, including four Nobel Laureates.” So I guess if there was any subjectivity on their part, it was Nobel Laureate–level subjectivity.
Karinsays
Agree with Franko – for example, a hyaluronic acid lip filler is really not new in any way.
Chris Newmarkersays
Thanks for the comment, Karin. So you think the Prix Galien USA Awards aren’t highlighting innovation the way they should?
I am not sure about this…. some contradictory experience reported…
https://www.odtmag.com/contents/view_breaking-news/2017-09-18/first-us-lawsuit-filed-against-depuy-synthes-for-attune-knee-replacement-failure/
Thanks for pointing out. Our sister publication MassDevice actually reported in September that some researchers found an “unusually high” rate of early failure related to the Attune knee systems tibial components. http://www.massdevice.com/report-depuys-attune-knee-seeing-unusually-high-rate-early-failure/ I added a mention of the news to the slide about Attune. Perhaps the Prix Galien USA Committee was too soon to highlight Attune as innovative?
I’d like to know how did you measure “innovative” properties of a medical device? What was the standard for measurement? Your list, looks very subjective and misleading.
Thanks for the comment, Balint. The list includes the 11 medical technology nominees for the 11th Annual Prix Galien USA Award from the Galien Foundation. They said the nominees were chosen by a judging committee of “13 renowned leaders from the biomedical industry and academia, including four Nobel Laureates.” So I guess if there was any subjectivity on their part, it was Nobel Laureate–level subjectivity.
Agree with Franko – for example, a hyaluronic acid lip filler is really not new in any way.
Thanks for the comment, Karin. So you think the Prix Galien USA Awards aren’t highlighting innovation the way they should?
These 11 innovations are great for the medical field.